Cepheid (NASDAQ:CPHD) shot up 5.5% during trading on Friday . The stock traded as high as $33.32 and last traded at $33.10, with a volume of 290,458 shares trading hands. The stock had previously closed at $31.37.

Several brokerages have commented on CPHD. Zacks Investment Research lowered shares of Cepheid from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th. Canaccord Genuity reiterated a “hold” rating and set a $32.00 price objective on shares of Cepheid in a research note on Wednesday, June 29th. Morgan Stanley assumed coverage on shares of Cepheid in a research note on Wednesday, June 15th. They set an “equal weight” rating and a $30.00 price objective on the stock. TheStreet lowered shares of Cepheid from a “hold” rating to a “sell” rating in a research note on Monday, June 6th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Cepheid in a research note on Saturday, April 30th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $41.58.

The firm’s market cap is $2.43 billion. The firm’s 50-day moving average price is $29.02 and its 200-day moving average price is $31.15.

Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Thursday, April 28th. The company reported $0.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.07. The business had revenue of $144.80 million for the quarter, compared to the consensus estimate of $140.35 million. The company’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period last year, the firm earned $0.17 earnings per share. Analysts forecast that Cepheid will post $0.25 earnings per share for the current fiscal year.

In related news, CEO John L. Bishop sold 110,000 shares of the business’s stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $35.50, for a total transaction of $3,905,000.00. Following the completion of the transaction, the chief executive officer now owns 194,449 shares in the company, valued at $6,902,939.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Scott A. Campbell sold 2,058 shares of the business’s stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $27.90, for a total transaction of $57,418.20. Following the transaction, the vice president now owns 13,761 shares of the company’s stock, valued at approximately $383,931.90. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Mutual of America Capital Management LLC boosted its position in shares of Cepheid by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 55,353 shares of the company’s stock worth $2,022,000 after buying an additional 329 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Cepheid by 5.5% in the fourth quarter. Rhumbline Advisers now owns 86,191 shares of the company’s stock worth $3,149,000 after buying an additional 4,495 shares in the last quarter. CAM Group Holding A S boosted its position in shares of Cepheid by 1.9% in the fourth quarter. CAM Group Holding A S now owns 117,400 shares of the company’s stock worth $4,289,000 after buying an additional 2,180 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Cepheid by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 133,079 shares of the company’s stock worth $4,861,000 after buying an additional 2,171 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in shares of Cepheid by 3.5% in the fourth quarter. California Public Employees Retirement System now owns 179,500 shares of the company’s stock worth $6,557,000 after buying an additional 6,000 shares in the last quarter.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.